Biohaven

Biohaven(BHVN)

NEW HAVEN, CT
Biotechnology
WebsiteLinkedInCareers Page

Focus: Small Molecules for Neurology Indications

Biohaven is a life sciences company focused on Small Molecules for Neurology Indications.

Neurology
Funding Stage
PUBLIC
Open Jobs
0

Pipeline & Clinical Trials

N/A
Clinical Trials (1)
NCT03537807Expanded Access Protocol of BHV-0223 for Patients With Amyotrophic Lateral Sclerosis (ALS)
N/A
Optimized rehabilitation program
Spinal Muscular Atrophy
N/A
Clinical Trials (1)
NCT06419322Acceptability, Feasibility, Safety and Efficacy of a Optimized Rehabilitation Program for Treated Patients With Spinal Muscular Atrophy (SMA).
N/A
Troriluzole
SCA
N/A
Clinical Trials (1)
NCT06034886Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA)
N/A
BHV3241, verdiperstat
Multiple System Atrophy (MSA)
N/A
Clinical Trials (1)
NCT05086094Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)
N/A
N/A
Clinical Trials (1)
NCT06529146Real-World Data Study of Troriluzole-Treated Patients With Spinocerebellar Ataxia (SCA) Compared to a Matched Natural History Control
N/A
Phase 1
Clinical Trials (1)
NCT07054684Study of BHV-1400 in IgA Nephropathy
Phase 1
BHV-1530
Solid Tumor
Phase 1
Clinical Trials (1)
NCT06874335A Phase 1 Study of BHV-1530 in Advanced Solid Tumors
Phase 1
Troriluzole
Glioblastoma
Phase 1
Clinical Trials (1)
NCT06552260A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
Phase 1
Phase 1
Clinical Trials (1)
NCT06980649Study of BHV-1300 in Graves' Disease
Phase 1
BHV-1100 plus cytokine induced memory-like
Multiple Myeloma
Phase 1
Clinical Trials (1)
NCT04634435Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients
Phase 1
Phase 1
Clinical Trials (1)
NCT07262268A Phase 1b Study of BHV-7000 in Participants With Inherited Erythromelalgia
Phase 1
Phase 1
Clinical Trials (1)
NCT04616456Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients
Phase 1
BHV-700
Epilepsy
Phase 1
Clinical Trials (1)
NCT07125261BHV-7000 Responsive Neurostimulation System (RNS) Study
Phase 1
Phase 1
Clinical Trials (1)
NCT03520517Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS
Phase 1
BHV-1510
Solid Tumor
Phase 1/2
Clinical Trials (1)
NCT06384807A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors
Phase 1/2
BHV-2100
Migraine
Phase 2
Clinical Trials (1)
NCT06603623Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine
Phase 2
Taldefgrobep Alfa
Obesity
Phase 2
Clinical Trials (1)
NCT07281495Taldefgrobep Alfa in Adults With Overweight and Obesity
Phase 2
Ipilimumab
Melanoma
Phase 2
Clinical Trials (1)
NCT04899921Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets
Phase 2
Phase 2
Clinical Trials (1)
NCT03605667Study of BHV-4157 in Alzheimer's Disease
Phase 2
Phase 2
Clinical Trials (1)
NCT06443463Long-term Safety and Tolerability of BHV-7000
Phase 2
Phase 2
Clinical Trials (1)
NCT06423781Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)
Phase 2
Phase 2
Clinical Trials (1)
NCT06423794BHV-7000 Open-Label Extension Bipolar Mania Study
Phase 2
Phase 2
Clinical Trials (1)
NCT06419608Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression
Phase 2
Phase 2/3
Clinical Trials (1)
NCT03299166Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder
Phase 2/3
Phase 2/3
Clinical Trials (1)
NCT03017508Acute Anxiolytic Effects of Riluzole on Subjects With Social Anxiety Disorder
Phase 2/3
Phase 2/3
Clinical Trials (1)
NCT04436510HEALEY ALS Platform Trial - Regimen B Verdiperstat
Phase 2/3
Phase 2/3
Clinical Trials (1)
NCT06976268A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
Phase 2/3
Phase 2/3
Clinical Trials (1)
NCT06309966Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
Phase 2/3
Phase 2/3
Clinical Trials (1)
NCT06419582BHV-7000 Acute Treatment of Bipolar Mania
Phase 2/3
Phase 2/3
Clinical Trials (1)
NCT06132893A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
Phase 2/3
Phase 2/3
Clinical Trials (1)
NCT06425159A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures
Phase 2/3
Temozolomide
Glioblastoma
Phase 2/3
Phase 2/3
Clinical Trials (1)
NCT02960893Trial in Adult Participants With Spinocerebellar Ataxia (SCA)
Phase 2/3
taldefgrobep alfa
Spinal Muscular Atrophy
Phase 3
Clinical Trials (1)
NCT05337553A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy
Phase 3
Phase 3
Clinical Trials (1)
NCT04641143Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder
Phase 3
Phase 3
Clinical Trials (1)
NCT03829241Randomized Trial of Adult Participants With Generalized Anxiety Disorder
Phase 3
Phase 3
Clinical Trials (1)
NCT03701399Troriluzole in Adult Participants With Spinocerebellar Ataxia
Phase 3
Phase 3
Clinical Trials (1)
NCT03952806Study of BHV-3241 in Participants With Multiple System Atrophy
Phase 3
Phase 3
Clinical Trials (1)
NCT04693351Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder
Phase 3
Phase 3
Clinical Trials (1)
NCT04708834Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder
Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 39 clinical trials
SEC Filings: 2 available

Financials (FY2025)

R&D Spend
$373M15%
Net Income
-$408M
Cash
$248M
Source: SEC 10-K Filing